These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16003843)

  • 1. Face to face with lipoatrophy. An interview with David Nolan by Nelson Vergel.
    Nolan D
    GMHC Treat Issues; 2005; 19(3-4):1-6. PubMed ID: 16003843
    [No Abstract]   [Full Text] [Related]  

  • 2. Complications & side effects. Nukes and fat wasting.
    TreatmentUpdate; 2004; 16(7):3-4. PubMed ID: 17225282
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogenesis of HIV-associated lipodystrophy.
    Wanke C
    AIDS Clin Care; 2000 Dec; 12(12):100. PubMed ID: 12211161
    [No Abstract]   [Full Text] [Related]  

  • 4. The latest word on lipodystrophy and mitochondrial toxicity (and old words that still resound).
    Mascolini M
    IAPAC Mon; 2002 Jan; 8(1):14-32. PubMed ID: 11858198
    [No Abstract]   [Full Text] [Related]  

  • 5. Side effects and complications. Does switching therapy away from d4T help the face?
    TreatmentUpdate; 2005 Dec; 17(7):2-3. PubMed ID: 17223668
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment: reversing lipoatrophy--better solutions needed.
    McComsey G
    AIDS Read; 2004 Dec; 14(12):648-9. PubMed ID: 15619780
    [No Abstract]   [Full Text] [Related]  

  • 7. It's time to face the Zerit problem.
    Vergel N
    GMHC Treat Issues; 2003 Mar; 17(3):12. PubMed ID: 12728861
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipodystrophy update--the continuing saga.
    Proj Inf Perspect; 2001 Mar; (32):9-10. PubMed ID: 11682779
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Leading to lipodystrophy.
    TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipodystrophy--introduction.
    TreatmentUpdate; 2001; 13(7):2-3. PubMed ID: 11794857
    [No Abstract]   [Full Text] [Related]  

  • 11. The case against Zerit.
    Huff B
    GMHC Treat Issues; 2002 Oct; 16(10):1-4. PubMed ID: 12458548
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipodystrophy update.
    Proj Inf Perspect; 2002 Mar; (34):7-8. PubMed ID: 12038302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing nuke toxicity.
    TreatmentUpdate; 2002 Mar; 14(3):3-4. PubMed ID: 12033187
    [No Abstract]   [Full Text] [Related]  

  • 14. Fat loss prompts SA treatment switch.
    IAPAC Mon; 2006 Jul; 12(7):212. PubMed ID: 17096492
    [No Abstract]   [Full Text] [Related]  

  • 15. Complications and side effects. Minimizing fat loss--comparing nukes.
    TreatmentUpdate; 2007; 19(5):6. PubMed ID: 17955615
    [No Abstract]   [Full Text] [Related]  

  • 16. Longitudinal studies of the role of NRTIs in fat loss.
    Currier J
    AIDS Clin Care; 2002 Dec; 14(12):106-7. PubMed ID: 12510657
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipodystrophy: a new phenomenon?
    Boyle BA
    AIDS Read; 1999; 9(1):15-7. PubMed ID: 12728877
    [No Abstract]   [Full Text] [Related]  

  • 18. Complications & side effects. Lipodystrophy: yesterday, today and tomorrow.
    TreatmentUpdate; 2004; 16(7):1-3. PubMed ID: 17219683
    [No Abstract]   [Full Text] [Related]  

  • 19. Report from the 12th Retrovirus Conference. Metabolic complications.
    Henry K
    AIDS Clin Care; 2005 Apr; 17(4):37-8. PubMed ID: 15875312
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection from nuke side effects.
    TreatmentUpdate; 2002 Dec; 14(9):3-4. PubMed ID: 12593383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.